Patents by Inventor Brian Francis SULLIVAN
Brian Francis SULLIVAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230125427Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.Type: ApplicationFiled: April 13, 2022Publication date: April 27, 2023Inventors: Lance Gavin LAING, Brian Francis SULLIVAN
-
Publication number: 20230022525Abstract: Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.Type: ApplicationFiled: July 25, 2022Publication date: January 26, 2023Inventors: Brian Francis SULLIVAN, Lance Gavin LAING
-
Publication number: 20220412957Abstract: Provided herein are methods for determining the functional status of G-protein coupled receptor (GPCR) signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a RAS node or receptor tyrosine kinase (RTK) targeted therapeutic. Also provided are methods for determining whether a GPCR signaling pathway is ultrasensitive in a diseased cell sample from a subject. Methods of administering a selected RAS node or RTK targeted therapeutic agent to the subject are also provided.Type: ApplicationFiled: June 8, 2022Publication date: December 29, 2022Inventors: Lance Gavin LAING, Salmaan Ahmed KHAN, Brian Francis SULLIVAN
-
Patent number: 11333659Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.Type: GrantFiled: August 29, 2018Date of Patent: May 17, 2022Assignee: Celcuity Inc.Inventors: Lance Gavin Laing, Brian Francis Sullivan
-
Patent number: 11073509Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.Type: GrantFiled: June 10, 2016Date of Patent: July 27, 2021Assignee: Celcuity Inc.Inventors: Lance Gavin Laing, Brian Francis Sullivan
-
Publication number: 20210215673Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: ApplicationFiled: March 5, 2021Publication date: July 15, 2021Inventors: Lance Gavin Laing, Brian Francis Sullivan
-
Patent number: 10976307Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: GrantFiled: July 3, 2018Date of Patent: April 13, 2021Assignee: Celcuity Inc.Inventors: Lance Gavin Laing, Brian Francis Sullivan
-
Publication number: 20190025287Abstract: Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.Type: ApplicationFiled: August 29, 2018Publication date: January 24, 2019Inventors: Lance Gavin LAING, Brian Francis SULLIVAN
-
Publication number: 20180321222Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: ApplicationFiled: July 3, 2018Publication date: November 8, 2018Inventors: Lance Gavin LAING, Brian Francis SULLIVAN
-
Patent number: 10041934Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: GrantFiled: June 24, 2016Date of Patent: August 7, 2018Assignee: Celcuity LLCInventors: Lance Gavin Laing, Brian Francis Sullivan
-
Publication number: 20170343554Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.Type: ApplicationFiled: December 14, 2015Publication date: November 30, 2017Applicant: Celcuity LLCInventors: Brian Francis SULLIVAN, Lance Gavin LAING
-
Publication number: 20170067875Abstract: Provided herein are methods for determining the functional status of a cellular pathway in a diseased cell sample obtained from an individual subject. These methods involve contacting a diseased cell sample obtained from the subject with a perturbing agent (e.g., an activating agent) known to perturb a specific cellular pathway when the pathway is functioning normally. A change in one or more physiological response parameters in the presence of the perturbing agent indicates that the cellular pathway targeted by the perturbing agent is functional in the individual subject. Methods of selecting a targeted therapeutic agent for an individual subject are also provided.Type: ApplicationFiled: June 10, 2016Publication date: March 9, 2017Inventors: Lance Gavin LAING, Brian Francis SULLIVAN
-
Publication number: 20160305932Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: ApplicationFiled: June 24, 2016Publication date: October 20, 2016Inventors: Lance Gavin LAING, Brian Francis SULLIVAN
-
Patent number: 9404915Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: GrantFiled: January 6, 2015Date of Patent: August 2, 2016Assignee: Celcuity LLCInventors: Lance Gavin Laing, Brian Francis Sullivan
-
Patent number: 9124935Abstract: A television signals receiver for receives and stores television signals encoded at a variable data rate. Time information is generated based on the time of receipt of the signals that defines the duration of the television signals when output in decompressed form at a substantially constant data rate. The received signals are then written to a file on a hard disk (13) in received order together with the time information. The time information of signals stored in the file is monitored and old signals are deleted from the file such that the file stores signals corresponding to a predetermined period of time.Type: GrantFiled: November 13, 2002Date of Patent: September 1, 2015Assignee: BRITISH SKY BROADCASTING LTD.Inventors: Xavier Willame, Nigel Bodkin, Nicholas James, Ellen Fiona Collins, Benjamin Johnathan Freeman, Brian Francis Sullivan
-
Patent number: 9113209Abstract: A television signals receiver for receives and stores television signals encoded at a variable data rate. Time information is generated based on the time of receipt of the signals that defines the duration of the television signals when output in decompressed form at a substantially constant data rate. The received signals are then written to a file on a hard disk 13 in received order together with the time information. The time information of signals stored in the file is monitored and old signals are deleted from the file such that the file stores signals corresponding to a predetermined period of time.Type: GrantFiled: December 2, 2011Date of Patent: August 18, 2015Assignee: BRITISH SKY BROADCASTING LTDInventors: Xavier Willame, Nigel Bodkin, Nicholas James, Ellen Fiona Collins, Benjamin Johnathan Freeman, Brian Francis Sullivan
-
Patent number: 9084017Abstract: A television signals receiver for receives and stores television signals encoded at a variable data rate. Time information is generated based on the time of receipt of the signals that defines the duration of the television signals when output in decompressed form at a substantially constant data rate. The received signals are then written to a file on a hard disk 13 in received order together with the time information. The time information of signals stored in the file is monitored and old signals are deleted from the file such that the file stores signals corresponding to a predetermined period of time.Type: GrantFiled: December 2, 2011Date of Patent: July 14, 2015Assignee: BRITISH SKY BROADCASTING LTD.Inventors: Xavier Willame, Nigel Bodkin, Nicholas James, Ellen Fiona Collins, Benjamin Johnathan Freeman, Brian Francis Sullivan
-
Publication number: 20150125894Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: ApplicationFiled: January 6, 2015Publication date: May 7, 2015Inventors: Lance Gavin LAING, Brian Francis SULLIVAN
-
Publication number: 20130330761Abstract: The disclosure provides methods for analysis of disease cell response to a therapeutic agent. In embodiments, a method comprises administering the therapeutic agent to a disease cell sample from the subject in a device that measures at least one physiological parameter of a cell; determining whether a change occurs in the physiologic parameter of the disease cell sample in response to the therapeutic agent as compared to a baseline measurement or the physiological parameter before administration of the therapeutic agent, and selecting the therapeutic agent that results in the change in the at least one physiologic parameter. In embodiments, the disease cells are whole, viable, and/or label free.Type: ApplicationFiled: June 12, 2012Publication date: December 12, 2013Applicant: Celcuity, LLCInventors: Lance Gavin Laing, Brian Francis Sullivan
-
Publication number: 20130071092Abstract: A receiver for television signals receives and stores television signals encoded at a variable data rate. Time information is generated based on the time of receipt of the signals that defines the duration of the television signals when output in decompressed form at a substantially constant data rate. The received signals are then written to a file on a hard disk in received order together with the time information. The time information of signals stored in the file is monitored and old signals are deleted from the file such that the file stores signals corresponding to a predetermined period of time.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: BRITISH SKY BROADCASTING LTD.Inventors: Xavier WILLAME, Nigel BODKIN, Nicholas JAMES, Ellen Fiona COLLINS, Benjamin Johnathan FREEMAN, Brian Francis SULLIVAN